Patient-derived Organoids of Lung Cancer to Test Drug Response
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorUniversity Hospital, Geneva
About this trial
This is a single center, single arm, open and exploratory clinical study, with 50 cases planned for a period of 3 years. The purpose of this study is to evaluate the consistency and accuracy of a Patient-Derived Organoid (PDO) Model of lung cancer to predict the clinical efficacy of anti-cancer drugs, in order to predict the best chemotherapy regimen for each given patient.
Eligibility criteria
Qualifiers
Histologically proven lung cancer
Age ≥ 18
Written informed and signed consent
Accessible to biopsy and/or surgery sample of metastasis and/or primitive tumour
Disqualifiers
Less than 18 years of age
Not able to give informed consent (language, intellectual capacities, etc.)
Not accessible to biopsy and/or surgery sample
Not enough lung tissue for a histological analysis or the remaining lung tissue is not enough to perform a routine pathological analysis.
Trial design
Treatments tested in this trial
- Lung tumor resection
Treatment groups
No treatment groups listed
Sponsors and collaborators
Source ClinicalTrials.gov